The HER2 status of a tumor highly determines the response to treatment, since it is associated with high aggressiveness; moreover, a high fraction of patients who initially responded to the trastuzumab therapy developed resistance to this agent during the first year of treatment [82]. The gene discussed is ERBB2; the disease is neoplasm.